Compare · DFTX vs UPXI
DFTX vs UPXI
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Upexi Inc. (UPXI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and UPXI operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.83B, about 81.7x UPXI ($59.1M).
- Over the past year, DFTX is up 345.2% and UPXI is down 90.2% - DFTX leads by 435.4 points.
- UPXI has been more active in the news (6 items in the past 4 weeks vs 5 for DFTX).
- DFTX has more recent analyst coverage (5 ratings vs 2 for UPXI).
PerformanceDFTX+345.17%UPXI-90.19%
2025-07-21+0.00%2026-07-17
- Company
- Definium Therapeutics Inc.
- Upexi Inc.
- Price
- $44.25+0.35%
- $0.80-3.39%
- Market cap
- $4.83B
- $59.1M
- 1M return
- +83.23%
- -17.48%
- 1Y return
- +345.17%
- -90.19%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 5
- 6
- Recent ratings
- 5
- 2
Latest DFTX
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
- New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
- Definium Therapeutics Announces New Employee Inducement Grants
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Chief Legal Officer Sullivan Mark sold $585,750 worth of shares (13,008 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 320,571 units (SEC Form 4) (withholding tax)
- Chief Medical Officer Karlin Daniel sold $451,876 worth of shares (10,035 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 503,282 units (SEC Form 4) (withholding obligation)
- Chief Financial Officer Roberts Brandi sold $135,675 worth of shares (3,013 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 209,487 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Barrow Robert sold $1,315,236 worth of shares (29,208 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,098,246 units (SEC Form 4) to satisfy withholding obligation
- Chief Commercial Officer Wiley Matthew T. sold $129,101 worth of shares (2,867 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 174,633 units (SEC Form 4) (withholding obligation)
Latest UPXI
- SEC Form EFFECT filed by Upexi Inc.
- SEC Form 424B3 filed by Upexi Inc.
- SEC Form S-3 filed by Upexi Inc.
- Upexi Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Upexi Partners with Blueprint to Stake Solana Treasury Assets
- SEC Form D filed by Upexi Inc.
- Upexi Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits
- Upexi Added to the Russell Microcap® Index
- Upexi Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Upexi Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits